IQV stock forecast, quote, news & analysis
Iqvia is a global leader in clinical research and technology solutions for the life science industry... Show more
IQVIA Holdings (IQV) Stock Analysis: AI-Powered Growth Narrative Gains Momentum Ahead of Q2 Earnings
Key Takeaways
- IQVIA shares climbed approximately 8.8% over the past 30 days, with the stock rising from around $191 to close at $208.05 on July 24, 2026.
- The company's AI-driven strategy is gaining traction, with 19 of the top 20 global pharmaceutical companies now using IQVIA's specialized AI agents across 64 commercial and R&D use cases.
- Analyst sentiment remains broadly positive, with a consensus Moderate Buy rating and an average price target of approximately $225.71 — Baird recently raised its target to $249.
- Q2 2026 earnings are scheduled for release on July 28 before market open, with consensus estimates pegged at $3.02 EPS on $4.3 billion in revenue.
- A $2 billion share repurchase authorization announced in May signals management's confidence in the stock's valuation, with the total remaining authorization reaching $3.2 billion.
Current Market Snapshot
IQVIA Holdings has demonstrated notable resilience through mid-2026, with shares recovering from a mid-June dip near $162 to trade firmly above the $200 mark by late July. The stock's 50-day moving average sits around $188, while its 200-day moving average is approximately $187, placing the current price comfortably above both key technical levels. Over the past year, IQV has risen roughly 26%, outpacing the broader healthcare services sector. The company's $34.8 billion market capitalization reflects its standing as one of the largest clinical research organizations and healthcare data providers globally. Investor attention is now squarely focused on the upcoming Q2 earnings report, where AI adoption metrics and backlog conversion rates will be closely scrutinized.
IQVIA Holdings (IQV) Business Overview and Competitive Position
IQVIA Holdings is a leading global provider of clinical research services, advanced analytics, and healthcare intelligence to the life sciences industry. Formed through the 2016 merger of Quintiles and IMS Health, the company operates through two primary segments: Research & Development Solutions, which provides outsourced clinical development services across phases I–IV, and Commercial Solutions, which delivers data-driven commercial strategy, real-world evidence, and technology platforms. With approximately 93,000 employees across more than 100 countries, IQVIA's competitive moat rests on its vast healthcare data assets, its IQVIA Connected Intelligence platform, and its Healthcare-grade AI capabilities. The company's R&D contracted backlog stood at $34.2 billion as of March 31, 2026, providing substantial multi-year revenue visibility that few competitors can match. This combination of scale, data depth, and technological integration has made IQVIA a critical partner for pharmaceutical companies navigating increasingly complex drug development and commercialization landscapes.
Recent Developments Driving IQV
Several catalysts have shaped IQVIA's stock performance in recent weeks. On July 1, Robert W. Baird raised its price target on IQV from $230 to $249 while maintaining an Outperform rating and naming the stock a "Bullish Fresh Pick," citing the company's positioning at the intersection of AI and clinical trials. HSBC and Deutsche Bank also set $240 price targets earlier in July, reinforcing the bullish analyst consensus. The company's first-quarter 2026 results, reported in early May, exceeded expectations with revenue of $4.15 billion (up 8.4% year-over-year) and adjusted EPS of $2.90, beating estimates by $0.07. Commercial Solutions revenue surged 11.6% year-over-year, driven by strong demand for AI-enabled offerings and data-as-a-service platforms. IQVIA also priced €950 million in senior notes at 4.625% in early June to refinance existing debt, improving its balance sheet flexibility. The $2 billion share buyback expansion announced on May 7 brought total remaining authorization to $3.2 billion, and the company repurchased $552 million in stock during Q1 alone. Meanwhile, MEDP and WST — peers in the life sciences tools and services space — have also reported Q2 results, with Medpace beating estimates and trading higher, offering a positive read-through for the sector heading into IQVIA's own earnings report.
Trending AI Robots
Investors looking to complement their own research with algorithm-driven insights may find value in Tickeron's Trending AI Robots page. Tickeron offers hundreds of AI-powered trading bots that actively trade thousands of tickers across multiple asset classes, but only the top-performing and most relevant strategies are showcased in this curated section. These bots vary by trading style, time horizon, and performance metrics — ranging from short-term momentum strategies to longer-term trend-following approaches — allowing users to observe how AI models interpret real-time market data across different market conditions. The page is designed to help traders and investors identify which automated strategies are currently resonating with prevailing market dynamics.
2026 Outlook and What Investors Should Watch
IQVIA's immediate catalyst is its Q2 2026 earnings report on July 28, where investors will focus on organic revenue growth rates, AI adoption metrics, and the trajectory of the R&D Solutions backlog conversion. The company's full-year guidance calls for revenue between $17.15 billion and $17.35 billion and adjusted EPS of $12.65 to $12.95 — both metrics that will be tested against a backdrop of stabilizing pharmaceutical R&D spending following several years of post-COVID turbulence. Key risk factors include IQVIA's elevated net leverage ratio of 3.62x, weak near-term liquidity with a current ratio of 0.75, and any potential slowdown in biopharma discretionary spending tied to macroeconomic headwinds or regulatory shifts. On the opportunity side, the company's 192 specialized AI agents, multi-year data-as-a-service contracts, and $8.9 billion in expected twelve-month backlog conversion provide meaningful visibility into future revenue. The life sciences industry's structural shift toward AI-integrated drug development and real-world evidence generation positions IQVIA favorably for the remainder of 2026 and beyond.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IQV's Stochastic Oscillator driving into overbought zone
The Stochastic Oscillator for IQV moved into overbought territory on August 13, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for IQV moved out of overbought territory on July 31, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IQV broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 13, 2026. You may want to consider a long position or call options on IQV as a result. In of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IQV just turned positive on July 28, 2026. Looking at past instances where IQV's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
The 50-day moving average for IQV moved above the 200-day moving average on August 06, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 218 cases where IQV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.443) is normal, around the industry mean (69.022). P/E Ratio (30.040) is within average values for comparable stocks, (150.346). Projected Growth (PEG Ratio) (0.992) is also within normal values, averaging (1.672). IQV has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). P/S Ratio (2.420) is also within normal values, averaging (8.434).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical development services and commercial outsourcing services
Industry MedicalSpecialties